Pregnancy outcomes after early fetal exposure to injectable first-line treatments, dimethyl fumarate, or natalizumab in Danish women with multiple sclerosis.

ABSTRACT:

Background and purpose

Data on pregnancy outcomes following fetal exposure to disease-modifying drugs (DMDs) in women with multiple sclerosis (MS) are sparse although growing.

Methods

Data from the Danish Multiple Sclerosis Registry were linked with nationwide registries enabling an investigation of adverse pregnancy outcomes in newborns of women with MS following fetal exposure to injectable first-line treatments, dimethyl fumarate, glatiramer acetate, or natalizumab. Logistic regression models accounting for clustered data were used to estimate odds ratios (ORs) with 95% confidence intervals (CIs) for individual and composite adverse outcomes after adjusting for relevant covariates.

Results

A total of 1009 DMD-exposed pregnancies were compared with 1073 DMD-unexpose

SUBMITTER: Andersen JB 

PROVIDER: S-EPMC10092676 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature